Oxford Biomedica., Thermo Fisher Scientific, Inc. and Merck KGaA are Dominating the Global Lentiviral Vector Market in 2020

Global Lentiviral Vector Market is expected to grow with the CAGR of 15.8% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-lentiviral-vector-market

Global lentiviral vector market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in global lentiviral vector market are introducing strong range of products provider along with launching new products and adopting strategic initiative such as acquisition, agreement, business expansion, award and recognition into the market. This helped companies to maximize the sales with enhanced product portfolio.

For instance:

  • In January 2021, Thermo Fisher Scientific, Inc. completed Henogen S.A., Novasep's viral vector manufacturing business in Belgium. It is predicted that this acquisition is anticipated to enhance viral vector production and significantly elevate its credibility in the global market.

Oxford Biomedica is the dominating player in global Lentiviral Vector market. The other key players existing in the market are Applied Biological Materials Inc., Creative Biolabs, bluebird bio, Inc., System Biosciences, LLC, Cobra Biologics Limited, FUJIFILM Diosynth Biotechnologies (a subsidiary of FUJIFILM Holdings Corporation), Sirion-Biotech GmbH, Merck KGaA, FinVector Oy, OriGene Technologies, Inc., Sino Biological Inc., Cell Biolabs, Inc., Batavia Biosciences B.V., Lonza, GENEMEDI, Takara Bio Inc., Thermo Fisher Scientific Inc., Waisman Biomanufacturing, and Cytiva (a subsidiary of Danaher) among others.

Lentiviral Vector Market

Oxford Biomedica.

Oxford Biomedica was founded in the year 1995. Oxford Biomedic’s headquarter is in Oxford, U.K. The company is exclusively focusing on gene and cell therapy business. The company operates its business via several business segments including platform and product in which platform is the market focused segment. The company has several product categories including LentiVector platform, TRiP system, LentiStable, SecNuc, process development, analytics, commercially approved vectors, automation and system integration, digitalisation and machine learning in which LentiVector platform, TRiP system, LentiStable are the market focused category.

For instance,

  • In April 2021, Oxford Biomedica signed a new three-year Development & Supply Agreement with Boehringer Ingelheim to manufacture and supply viral vectors. It is predicted that this agreement is anticipated to enhance the company's sales growth in the coming years.

The company has wide presence across Europe. The company also has various subsidiary companies Oxford Biomedica (U.K.) Limited (Great Britain), Oxford Biomedica (Ireland) Limited (Ireland), Oxxon Therapeutics Limited (Great Britain) and others.

Thermo Fisher Scientific, Inc.

Thermo Fisher Scientific, Inc. was founded in the year 2006 and is headquartered in Massachusetts, U.S. Their main focuses of the company is on making the world healthier, cleaner and safer by enabling their customers and support them in improving patient’s therapies and diagnostics. The company working on product categories which are life science, industrial and applied science, clinical & diagnostics, lab solutions, digital solutions in which clinical & diagnostics and life science are the market focused category.

For instance,

  • In February 2021, Thermo Fisher Scientific, Inc. announced it had won six awards in the annual CMO Leadership Awards. The awards, presented by life science leader and outsourced pharma, recognize top contract manufacturing partners as evaluated by biopharma and biotech companies. It is estimated that this recognition is anticipated to strengthen its footprints globally and lead to an upsurge in its growth in the coming years.

The company has presence across Asia-Pacific, Europe, Middle East and Africa, Americas. The company also has various subsidiaries including Thermo Fisher Scientific Operating Company LLC (U.S.), Thermo Fisher Scientific Senior Financing LLC (U.S.), Thermo Fisher Scientific (U.S.) Holding S.a.r.l. (Luxembourg), Laboratory Management Systems, Inc. (U.S.) and others.

Merck KGaA

Merck KGaA was founded in the year 1668 and is headquartered in Darmstadt, Germany. The main focus of the company is to drive towards their purpose by making progress in technologies that benefits all human lives by providing them their research and products. The company operates its business via several business segments including life science, healthcare and electronics in which life science is the market focused segment. The company has two product categories which are analytics and sample preparation, biopharmaceutical manufacturing, industrial microbiology, IVD/OEM materials and reagents, life science research, reagents, chemicals and labware, small molecule pharmaceuticals, water purification in which biopharmaceutical manufacturing is the market focused category.

For instance,

  • In October 2020, Merck KGaA has bolstered its viral vector manufacturing capabilities with its VirusExpress lentiviral production platform launch. This new platform helps overcome lentiviral production challenges and reduces process development time by approximately 40 percent. This development has helped the company to elevate its growth in the market.

The company has presence across Asia-Pacific, Europe, Middle East and Africa, South America, North America. The company also has various subsidiaries including AZ Electronic Materials (Luxembourg), Merck Serono (Darmstadt, Germany), Merck Millipore (Burlington, U.S.), Serono, Sigma-Aldrich (Munich, Germany), Carbolabs and Versum Materials (Arizona, U.S.) among others.